Basic Lanoxin Information

• INN (International Nonproprietary Name): Digoxin.
• Brand Names Available In United Kingdom: Lanoxin; Digoxin tablets; oral elixir formulations.
• ATC Code: C01AA05.
• Drug Classification: Cardiac glycoside; Group V antiarrhythmic; inotropic agent.
• Prescription Status: Prescription-only (Rx) in all major markets.
• Forms & Dosages:
  • Tablets: 0.0625 mg, 0.125 mg, 0.25 mg.
  • Oral solution/elixir: 0.05 mg/mL.
  • Injection (ampoules): 0.25 mg/mL (2 mL).
• Standard Dosages:
  • Adults (heart failure, atrial fibrillation): 0.125–0.25 mg once daily, individualised by response and renal function.
  • Children: 5–10 mcg/kg/day orally, weight-based regimens and paediatric solution preferred.
• Dosage Adjustments: Children require weight-based dosing; elderly often start at lower doses due to reduced renal clearance; renal impairment requires substantial dose reduction and frequent monitoring; hepatic impairment usually does not require major adjustment if renal function is normal.
• Manufacturers In United Kingdom: GlaxoSmithKline (historical Lanoxin supply) and multiple generic manufacturers and suppliers such as Teva, Mylan, Amneal and regional generics.
• Registration Status In United Kingdom: Licensed by UK regulators with branded Lanoxin and generics available under MHRA licensing.
• Storage: Store tablets and ampoules at room temperature (20–25°C).
• Absolute Contraindications: Ventricular fibrillation, known hypersensitivity to digitalis glycosides, acute myocarditis, severe AV block or sick sinus syndrome unless paced.
• Common Side Effects: Nausea, vomiting, diarrhoea, dizziness, confusion, visual disturbance (yellow/blurred vision), and arrhythmias when toxic.
• Other Important Notes: Regular serum digoxin level monitoring is crucial to prevent toxicity and many drug–drug interactions must be checked before initiation.
• OTC / Rx Classification: Prescription-only (Rx).

Latest Research Highlights (UK & EU)

Clinicians ask whether new trials have changed how digoxin is used in the UK and Europe.

Recent research from 2022–2025 has largely been registry and observational cohort work rather than large new randomised trials.

European and UK registries continue to show symptomatic benefit and, in selected monitored cohorts, reductions in heart‑failure hospital admissions when digoxin is used alongside contemporary therapy.

There remains no consistent new randomised evidence demonstrating a mortality benefit beyond historical trials.

Safety analyses reported to national pharmacovigilance schemes emphasise renal impairment and polypharmacy as recurrent risk factors for toxicity.

MHRA Yellow Card summaries and EU pharmacovigilance updates have highlighted gastrointestinal upset, visual disturbance and arrhythmia reports, with frequent interaction reports involving clarithromycin, verapamil and amiodarone.

Key metrics tracked in these data include changes in heart‑failure admissions, rates of serum digoxin monitoring and counts of Yellow Card interaction reports.

These findings support continued selective use of digoxin (lanoxin / digoxin tablets) with careful monitoring rather than broad first‑line prescribing changes.

Clinical Effectiveness In The UK

Patients often want to know if lanoxin actually improves how they feel and whether it reduces admissions.

Within NHS practice, digoxin is used selectively as adjunctive therapy in chronic heart failure and for ventricular rate control in atrial fibrillation when beta‑blockers or calcium‑channel blockers are unsuitable.

Local cardiology audits and heart‑failure services commonly report improved breathlessness and exercise tolerance when doses are carefully adjusted and serum digoxin levels are monitored.

Effectiveness depends on managing the drug's narrow therapeutic index with lower starting doses in the elderly and patients with renal impairment.

NHS performance metrics that help track safe and effective use include readmission rates for heart failure, time in therapeutic range for serum digoxin levels, and Yellow Card reports per trust.

• NHS Outcome KPIs: Heart‑failure readmissions, digoxin serum‑level monitoring frequency, medication reconciliation at discharge.
• Monitoring Checklist: Baseline renal function, baseline electrolytes, planned serum digoxin check 1–2 weeks after initiation or dose change, periodic review thereafter.

Prescribers on NHS e‑prescription systems must indicate indication and monitoring schedule when initiating lanoxin or generic digoxin tablets.

Indications & Expanded Uses

People ask which conditions lanoxin is officially licensed for and when specialists might use it off‑label.

MHRA‑approved indications are chronic heart failure in adults and children aged five years and over, and rate control in atrial fibrillation in adults.

• Approved Indication → Typical Dose Range → Monitoring Needs.
• Heart Failure (adults): 0.125–0.25 mg once daily → Renal function, serum digoxin level, electrolytes.
• Atrial Fibrillation (rate control): 0.125–0.25 mg once daily titrated to response → Heart rate, digoxin level, renal monitoring.
• Paediatric Use (licensed ≥5 years) → 5–10 mcg/kg/day orally (use oral solution for accuracy) → Weight‑based monitoring and specialist paediatric cardiology oversight.

Off‑label or situational uses in UK practice include specialist paediatric weight‑based regimens, adjunctive symptomatic therapy in heart failure with reduced ejection fraction, and palliative control of dyspnoea or refractory AF where alternatives are unsuitable.

Off‑label use should have documented rationale, specialist input and a clear monitoring plan recorded in the clinical notes.

Composition & Brand Landscape

Patients and pharmacists need to know what is inside each product and how brands differ.

The active ingredient is digoxin (INN), commonly supplied as Lanoxin or generic digoxin tablets in the UK market.

NHS procurement usually favours generics for cost control, and primary‑care pharmacists should be aware of tariff categories and dispensing guidelines when substituting branded Lanoxin with generic digoxin.

Contraindications & Special Precautions

Patients frequently worry which conditions make lanoxin unsafe.

Absolute contraindications include ventricular fibrillation, known hypersensitivity to digitalis glycosides, acute myocarditis and severe AV block or sick sinus syndrome unless the patient has a pacemaker.

Relative risks that need monitoring include electrolyte disturbances such as hypokalaemia and hypomagnesaemia, renal impairment, thyroid disease and recent myocardial infarction.

Elderly patients require lower starting doses because renal clearance falls with age and polypharmacy raises interaction risk.

Practical patient advice in the UK includes reporting visual changes, severe nausea or palpitations immediately, keeping regular blood tests via GP or outpatient clinics and being cautious with concurrent QT‑prolonging medicines.

• Pharmacy counselling checklist: check renal function, review medicines for interactions, advise on signs of toxicity, and warn about driving only if dizziness or visual disturbance occurs.

Dosage Guidelines

How should lanoxin be dosed safely for different patients?

Adults are typically prescribed 0.125–0.25 mg once daily, with individualisation for age, weight and renal function.

Elderly patients usually start at the lower end of the range and are titrated by response and serum levels.

Paediatric dosing is weight based, at 5–10 mcg/kg/day orally, with loading regimens used in acute settings under specialist care.

For intravenous use, injections are 0.25 mg/mL ampoules and dosing must follow local acute‑care protocols with cardiac monitoring.

Missed dose advice is to take when remembered unless close to the next dose and never double up.

Overdose is life‑threatening and presents with severe GI upset, visual disturbance, confusion and arrhythmias; emergency care is required.

Interactions Overview

Many patients ask which medicines will affect lanoxin levels or raise risks.

High‑risk interacting medicines include amiodarone, verapamil, diltiazem and some macrolide antibiotics such as clarithromycin and azithromycin.

These interactions commonly increase serum digoxin concentration or potentiate arrhythmia risk, often via effects on P‑glycoprotein or renal clearance.

Drugs that cause hypokalaemia, such as loop and thiazide diuretics, increase the risk of digoxin toxicity.

Herbal remedies such as St John’s Wort may alter digoxin levels through induction of transport proteins and should be declared to clinicians.

• High‑Risk Interactions: amiodarone, verapamil, clarithromycin, azithromycin, certain SSRIs — monitor levels and consider dose adjustment.
• Pharmacy Checklist: review electronic prescribing warnings, counsel on signs of toxicity, and liaise with the prescriber before supply if interacting agents are present.

MHRA Yellow Card reports commonly cite antibiotic–digoxin interactions and polypharmacy as causes for suspected adverse events in elderly patients.

Cultural Perceptions & Patient Habits

What do UK patients commonly worry about when offered lanoxin?

Many older patients trust NHS clinicians and community pharmacists for clear dosing and monitoring instructions, and heart‑failure nurse services often provide written plans detailing serum‑level checks.

Online patient forums show mixed views; some patients report clear symptomatic benefits while others express fear about digitalis toxicity and visual symptoms.

Community pharmacists at major chains and independent pharmacies play an important role in adherence counselling, checking interactions and advising on missed doses.

• Common Patient Concerns: risk of toxicity, need for blood tests, interactions with antibiotics and diuretics, and confusion about tablet strengths.
• Recommended Counselling Script: explain indication, confirm dose (eg, 0.125 mg), describe common side effects and tell patients when to contact GP or NHS 111.

Carers often request written instructions and clear labelling when managing multiple medicines for older relatives, and electronic prescriptions via the NHS app simplify repeat ordering when monitoring plans are in place.

Availability & Pricing Patterns

Patients and pharmacies frequently ask where lanoxin can be obtained and how much it costs.

Digoxin and Lanoxin are prescription‑only medicines across the UK under MHRA licensing and are supplied via hospital pharmacies, community dispensaries and legitimate online pharmacies with valid prescriptions.

Generics are typically cheaper than branded Lanoxin and NHS procurement prefers generic substitution to control costs and maintain supply resilience.

Regional differences in prescription charges affect patient out‑of‑pocket cost, with England applying a per‑item charge for most patients while Scotland, Wales and Northern Ireland operate different exemption schemes.

In our online pharmacy, lanoxin is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Pharmacies should verify authenticity and expiry of injectable ampoules and track supplier stability when tendering for trust formularies.

Comparable Medicines And Preferences

Clinicians choosing a rate‑control or inotropic strategy usually weigh alternatives against digoxin.

For rate control in atrial fibrillation, first‑line agents in NHS practice are typically beta‑blockers such as bisoprolol or metoprolol, or nondihydropyridine calcium‑channel blockers such as verapamil or diltiazem.

Amiodarone is used as an alternative antiarrhythmic in selected cases.

Digitoxin is a related cardiac glycoside with a longer half‑life and more hepatic metabolism, and may be considered in specialist situations where renal clearance limits digoxin use.

NHS formularies often reserve digoxin for specific subgroups rather than first‑line across the board.

FAQ

How will I know my digoxin dose is right?

Your prescriber will usually start a low dose such as 0.125 mg, check renal function and serum digoxin levels and reassess symptoms and heart rate.

Can I take other medicines or herbal remedies?

Always tell your GP and pharmacist about all medicines and supplements because many interactions exist, especially with antibiotics, antiarrhythmics and diuretics.

What should I do if I miss a dose?

Take the dose when you remember unless it is close to the next scheduled dose and do not double up.

What are the signs of overdose?

Severe nausea, vomiting, blurred or yellow vision, confusion and palpitations are red flags and require immediate medical attention or contact with NHS 111.

Storage advice: keep tablets and ampoules at room temperature (20–25°C) and out of reach of children.

Guidelines For Proper Use

What should a pharmacist cover when counselling a patient starting lanoxin?

Confirm the indication, review all current medicines for interactions and explain the exact dose and timing including missed‑dose rules.

Emphasise the need for baseline and periodic renal function and serum digoxin checks and describe common side effects that warrant contact with GP or NHS 111.

Provide a written patient leaflet or use NHS.uk resources to reinforce counselling and encourage enrolment in heart‑failure or anticoagulation clinics where appropriate.

• Pharmacist Counselling Checklist: indication confirmation, medication review, dosing instructions, monitoring schedule, emergency signs and Yellow Card reporting information.
• Patient Handout Template: include tablet strength, dose, next blood test date, contact details for urgent advice and storage instructions.

Hospital discharge summaries must clearly flag digoxin dosing, monitoring plans and the responsible clinician to prevent missed monitoring after discharge.

Delivery Across United Kingdom